Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8784684 | 0.95 | METAP2 (0.40) | L3MBTL1ALDH1A1METAP2CYP2D6CTSK | |
| SCHEMBL4138474 | 0.93 | ALDH1A1 (0.38) | L3MBTL1ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL1009487 | 0.91 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1LMNAHSD17B10METAP2 | |
| SCHEMBL16732371 | 0.87 | METAP2 (0.40) | L3MBTL1ALDH1A1METAP2CYP2D6CTSK | |
| SCHEMBL11021965 | 0.85 | METAP2 (0.43) | L3MBTL1ALDH1A1METAP2CTSKNPSR1 | |
| SCHEMBL4425794 | 0.85 | METAP2 (0.43) | L3MBTL1ALDH1A1METAP2CTSKNPSR1 | |
| SCHEMBL16621534 | 0.84 | ALOX5 (0.35) | CTSK | |
| SCHEMBL9219750 | 0.83 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL4713295 | 0.82 | METAP2 (0.41) | ALDH1A1LMNAMETAP2CTSKNPSR1 | |
| SCHEMBL25381770 | 0.79 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1LMNAHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| CN-101360498-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2009-02-04 | — | — | CN | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | L3MBTL1 4809/4885ALDH1A1 4674/4885LMNA 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.